Showing results (251-260 of 294) with videos related to
Sort By:
Pageof 30
Frontiers in Oncology|February 17, 2023
A multicenter randomized trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer: Clinical study protocolStefano Cavalieri, Claudia Vener, Marissa LeBlanc, et al.Future Oncology (London, England)|June 4, 2020
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412Jean-Pascal Machiels, Yungan Tao, Barbara Burtness, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2026
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 StudyLisa Licitra, Makoto Tahara, Kevin Harrington, et al.Journal for Immunotherapy of Cancer|July 17, 2019
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)Ezra E W Cohen, R Bryan Bell, Carlo B Bifulco, et al.Cancers|October 28, 2023
The Role of Carbon Ion Therapy in the Changing Oncology Landscape-A Narrative Review of the Literature and the Decade of Carbon Ion Experience at the Italian National Center for Oncological HadrontherapyEster Orlandi, Amelia Barcellini, Barbara Vischioni, et al.The Oncologist|June 6, 2018
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck CancerMaura L Gillison, George Blumenschein, Jerome Fayette, et al.Oral Oncology|June 10, 2018
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionRobert L Ferris, George Blumenschein, Jerome Fayette, et al.The Lancet. Oncology|January 30, 2017
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trialDenis Soulières, Sandrine Faivre, Ricard Mesía, et al.European Journal of Cancer (Oxford, England : 1990)|November 13, 2021
Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohortPaolo Bossi, Annalisa Trama, Alice Bernasconi, et al.Endocrine|June 23, 2026
Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer centerElena Colombo, Elisa Ortolan, Stefano Cavalieri, et al.Pageof 30